- Home
- ASMB vs IVAC Comparison
ASMB vs IVAC Comparison
Compare ASMB & IVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- IVAC
- Stock Information
- Founded
- ASMB 2005
- IVAC 1990
- Country
- ASMB United States
- IVAC United States
- Employees
- ASMB N/A
- IVAC N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- IVAC Industrial Machinery/Components
- Sector
- ASMB Health Care
- IVAC Technology
- Exchange
- ASMB Nasdaq
- IVAC Nasdaq
- Market Cap
- ASMB 100.5M
- IVAC N/A
- IPO Year
- ASMB 2010
- IVAC 1995
- Fundamental
- Price
- ASMB $15.14
- IVAC $2.68
- Analyst Decision
- ASMB Buy
- IVAC Hold
- Analyst Count
- ASMB 2
- IVAC 1
- Target Price
- ASMB $35.00
- IVAC N/A
- AVG Volume (30 Days)
- ASMB 25.9K
- IVAC 149.7K
- Earning Date
- ASMB 11-07-2024
- IVAC 11-11-2024
- Dividend Yield
- ASMB N/A
- IVAC N/A
- EPS Growth
- ASMB N/A
- IVAC N/A
- EPS
- ASMB N/A
- IVAC N/A
- Revenue
- ASMB $28,326,000.00
- IVAC $65,569,000.00
- Revenue This Year
- ASMB $267.67
- IVAC N/A
- Revenue Next Year
- ASMB $46.15
- IVAC N/A
- P/E Ratio
- ASMB N/A
- IVAC N/A
- Revenue Growth
- ASMB N/A
- IVAC 28.52
- 52 Week Low
- ASMB $8.16
- IVAC $2.46
- 52 Week High
- ASMB $19.93
- IVAC $4.57
- Technical
- Relative Strength Index (RSI)
- ASMB 40.09
- IVAC 34.62
- Support Level
- ASMB $13.41
- IVAC $2.48
- Resistance Level
- ASMB $15.36
- IVAC $3.43
- Average True Range (ATR)
- ASMB 0.98
- IVAC 0.17
- MACD
- ASMB -0.23
- IVAC -0.03
- Stochastic Oscillator
- ASMB 41.07
- IVAC 22.68
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.